Original Article

You have full text access to this OnlineOpen article

Is breast cancer survival improving?

Trends in survival for patients with recurrent breast cancer diagnosed from 1974 through 2000

  1. Sharon H. Giordano M.D.1,†,*,
  2. Aman U. Buzdar M.D.1,
  3. Terry L. Smith M.S.2,
  4. Shu-Wan Kau B.S.N.1,
  5. Ying Yang M.S.2,
  6. Gabriel N. Hortobagyi M.D.1

Article first published online: 10 NOV 2003

DOI: 10.1002/cncr.11859

Issue

Cancer

Cancer

Volume 100, Issue 1, pages 44–52, 1 January 2004

Additional Information

How to Cite

Giordano, S. H., Buzdar, A. U., Smith, T. L., Kau, S.-W., Yang, Y. and Hortobagyi, G. N. (2004), Is breast cancer survival improving?. Cancer, 100: 44–52. doi: 10.1002/cncr.11859

Author Information

  1. 1

    Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

  2. 2

    Department of Biostatistics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

  1. †

    Fax: (713) 794-4385

*Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 424, Houston, TX 77030

Publication History

  1. Issue published online: 17 DEC 2003
  2. Article first published online: 10 NOV 2003
  3. Manuscript Accepted: 30 SEP 2003
  4. Manuscript Revised: 26 SEP 2003
  5. Manuscript Received: 29 AUG 2003

Funded by

  • Nellie B. Connally Breast Cancer Research Fund

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (113K)

REFERENCES

  • 1
    Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin. 2003; 53: 5–26.
    Direct Link:
  • 2
    Bonadonna G, Brusamolino E, Valagussa P, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med. 1976; 294: 405–410.
  • 3
    Fisher B, Carbone P, Economou SG, et al. 1-phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings. N Engl J Med. 1975; 292: 117–122.
  • 4
    Anonymous. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. Early Breast Cancer Trialists' Collaborative Group. N Engl J Med. 1988; 319: 1681–1692.
  • 5
    Anonymous. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998; 352: 930–942.
  • 6
    Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003; 21: 976–983.
  • 7
    Nabholtz JM, Senn HJ, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol. 1999; 17: 1413–1424.
  • 8
    Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344: 783–792.
  • 9
    O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol. 2002; 20: 2812–2823.
  • 10
    Buzdar AU, Blumenschein GR, Gutterman JU, et al. Postoperative adjuvant chemotherapy with fluorouracil, doxorubicin, cyclophosphamide, and BCG vaccine. A follow-up report. JAMA. 1979; 242: 1509–1513.
  • 11
    Buzdar AU, Blumenschein GR, Smith TL, et al. Adjuvant chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide, with or without bacillus Calmette-Guerin and with or without irradiation in operable breast cancer. A prospective randomized trial. Cancer. 1984; 53: 384–389.
    Direct Link:
  • 12
    Buzdar AU, Hortobagyi GN, Smith TL, et al. Adjuvant therapy of breast cancer with or without additional treatment with alternate drugs. Cancer. 1988; 62: 2098–2104.
    Direct Link:
  • 13
    Buzdar AU, Hortobagyi GN, Kau SW, et al. Adjuvant therapy with escalating doses of doxorubicin and cyclophosphamide with or without leukocyte alpha-interferon for Stage II or III breast cancer. J Clin Oncol. 1992; 10: 1540–1546.
  • 14
    Buzdar AU, Singletary SE, Booser DJ, Frye DK, Wasaff B, Hortobagyi GN. Combined modality treatment of Stage III and inflammatory breast cancer. M.D. Anderson Cancer Center experience. Surg Oncol Clin N Am. 1995; 4: 715–734.
  • 15
    Assikis V, Buzdar A, Yang Y, et al. A Phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma: final analysis with 10-year follow-up. Cancer. 2003; 97: 2716–2723.
    Direct Link:
  • 16
    Cox DR. Regression models and life-tables. J R Stat Soc B. 1972; 34: 187–220.
  • 17
    Clark GM, Sledge GW Jr., Osborne CK, McGuire WL. Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol. 1987; 5: 55–61.
  • 18
    Chia SK, Speers C, Kang A, et al. The impact of new chemotherapeutic and hormonal agents on the survival of women with metastatic breast cancer in a population based cohort [abstract]. Proc Am Soc Clin Oncol. 2003; 22: 22a.
  • 19
    Arveux P, Grosclaude P, Reyrat E, Velten M, Bardau V, Borella L. Breast cancer survival in France: a relative survival analysis based on 68,449 cases treated in the 20 French comprehensive cancer centers between 1980 and 1999 [Abstract]. Proc Am Soc Clin Oncol. 2003; 22: 3437a.
View Full Article (HTML) Get PDF (113K)